Jupiter Endovascular Secures $21 Million in Funding to Revolutionize Endovascular Medicine with Surgical Precision and Control

Jupiter Endovascular is thrilled to announce that we have successfully raised $21 million in our latest funding round, a significant milestone that underscores our commitment to revolutionizing the field of endovascular medicine. Located in the vibrant San Francisco Bay Area, our innovative startup is pioneering a new class of therapies, known as the endoportal procedure, which utilizes Endoportal Control to bridge the gap between surgical precision and minimally invasive interventions. For far too long, clinicians have faced limitations with traditional catheters, having to make compromises that could affect both the efficiency of their procedures and patient outcomes. This funding will allow us to accelerate the development and implementation of our cutting-edge technologies, expanding their application across various areas of cardiovascular disease. With this injection of capital from a diverse group of investors—including venture capital firms, private equity, corporate strategic partners, and angel investors with clinical expertise—we are poised to reimagine therapies that can enhance patient lives. At Jupiter Endovascular, our culture is rooted in innovation, teamwork, and agility, empowering us to explore new frontiers in medical technology. We are excited about the journey ahead and the opportunity to deliver on our vision of empowering clinicians with groundbreaking tools to provide patients the chance to live longer, fuller lives. Stay tuned as we embark on this transformative path, committed to making a lasting impact on healthcare.